Orion and Abzena announce exclusive commercial license for Abzena’s antibody

ORION CORPORATION PRESS RELEASE 23 OCTOBER 2025 at 15:30 EEST Orion and Abzena announce exclusive commercial license for Abzena’s antibody Orion Corporation (“Orion”) and Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive, focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad oncology-focused drug Research ...